NCT04997174

Brief Summary

This is a retrospective study to compare postoperative pain intensity in patients going laparoscopic colorectal surgery with Enhanced Recovery after Surgery (ERAS), without ERAS and open colorectal surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
162

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 30, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 9, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

October 18, 2021

Status Verified

October 1, 2021

Enrollment Period

2 months

First QC Date

July 30, 2021

Last Update Submit

October 9, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain intensity

    Pain score (Verbal Numerical Rating Scale: VNRS) after surgery, VNRS consists of 0-10, where 0 means no pain and 10 means worst pain imaginable

    Until discharge (5-7 days)

Secondary Outcomes (1)

  • Opioid

    Until discharge (5-7 days)

Study Arms (3)

ERAS

Patients undergoing laparoscopic colorectal surgery with ERAS

Drug: Celecoxib

Non ERAS

Patients undergoing laparoscopic colorectal surgery without ERAS

Open

Patients undergoing open colorectal surgery

Interventions

Patients in ERAS group received celecoxib

ERAS

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Group of interest: Laparoscopic colorectal surgery with Enhanced Recovery after Surgery (ERAS) program defined as patients undergoing laparoscopic colorectal surgery \[laparoscopic right / left hemicolectomy, laparoscopic low anterior resection, laparoscopic abdominoperineal resection (APR) and others\] under ERAS protocol. Control 1: Laparoscopic colorectal surgery without Enhanced Recovery after Surgery (ERAS) program defined as patients undergoing laparoscopic colorectal surgery \[laparoscopic right / left hemicolectomy, laparoscopic low anterior resection, laparoscopic abdominoperineal resection (APR) and others\] under conventional protocol. Control 2: Open colorectal surgery defined as patients undergoing open laparotomy for colorectal surgery \[open right / left hemicolectomy, open low anterior resection, open abdominoperineal resection (APR) and others\].

You may qualify if:

  • Patients undergoing colorectal surgery under ERAS program and those with the same sort of laparoscopic surgery without ERAS program as well as those with open colorectal surgery with complete required recorded data.

You may not qualify if:

  • \. Patients with incomplete required data on record.
  • \. Those with any major intraoperative or postoperative complications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sasikaan Nimmaanrat

Hat Yai, Changwat Songkhla, 90110, Thailand

RECRUITING

Related Publications (1)

  • Tan SJ, Zhou F, Yui WK, Chen QY, Lin ZL, Hu RY, Gao T, Li N. Fast track programmes vs. traditional care in laparoscopic colorectal surgery: a meta-analysis of randomized controlled trials. Hepatogastroenterology. 2014 Jan-Feb;61(129):79-84.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Celecoxib

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

BenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur CompoundsPyrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Sasikaan Nimmaanrat, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 30, 2021

First Posted

August 9, 2021

Study Start

October 1, 2021

Primary Completion

December 1, 2021

Study Completion

December 1, 2022

Last Updated

October 18, 2021

Record last verified: 2021-10

Locations